Chitomur®
The condition of patients with BPH after treatment with CHITOMUR® was characterized by an im-
provement in subjective and objective indicators of urodynamics.
It should be noted that uroflograms recorded after treatment in patients with BPH stages I and II
showed the restoration of the basic parameters of urination to normal values. At stage III of the dis-
ease, this was prevented by a decrease in the elasticity of the bladder neck due to sclerotic changes
in the tissue of the prostate gland. Still, a noticeable increase in the urine stream was observed in
such patients.
The patients’ assessment of their bladder condition significantly improved. In women with climacteric
syndrome, accompanied by an overactive bladder, the use of CHITOMUR® achieved a 38% reduction
in urgency and incontinence episodes by 43%. The degree of discomfort due to imperative symptoms
decreased 1.8 times, the degree of anxiety decreased by 57%, and satisfaction with treatment reached
78%. Thus, according to the patients’ self-esteem, the decrease in anxiety caused by the symptoms
of urinary dysfunction is 1.8 times, comes ahead of the very positive dynamics of these symptoms,
which indicates a predominant improvement in the quality of life of women as a result of treatment.
A month after the course of treatment using CHITOMUR®, all patients retained the improvement in
symptoms. After discontinuation of the drug, the bladder capacity increased by 10-20% with various
urges to urinate, which is explained by a decrease in detrusor ischemia, which plays a significant role
in the pathogenesis of OAB.
Thus, the results of this study indicate the therapeutic efficacy of CHITOMUR® and the practicality
of its use in the complex treatment of dysuric disorders of various origins, including in diseases of the
prostate gland in men and women with symptoms of an overactive bladder.
CHITOMUR® does not cause side effects, complications, or drug dependence and can be used for
therapeutic and prophylactic purposes, combined with any means of symptomatic therapy used in
urological practice (antibacterial agents, antispasmodics, vascular and hormonal drugs, vitamins, etc.)
CONCLUSION
Biologically active food supplement CHITOMUR® has a regulating effect on the functional activity of
the cells of the wall and detrusor cells of the bladder and helps normalize urination function.
CHITOMUR®is well tolerated when taken orally, has no side effects, and can be used as a therapeutic
and prophylactic biologically active food supplement.
CHITOMUR®is recommended for patients with impaired urination function of various origins - oral-
ly during meals, 1-2 capsules or tablets 2 times a day for 30 days. It is recommended to repeat the
course of treatment in 3-6 months.
REFERENCES
1. Mashkovsky M.D., Medicines: Pharmacotherapy for doctors, manual: 2 parts. – Vilnius: ZAO “Gam-
ta”, 1993.
2. Guide to Andrology / Ed. O. L. Tiktinsky. - L.: Medicine, 1990. -- 416 p.
3. Sexopathology: A Handbook / Ed. G.S. Vasilchenko. - M.: Medicine, 1990. -- 576 p.
Для таблиц, дозировок и примечаний сверяйтесь с оригинальным PDF: при извлечении текста порядок колонок может измениться.
Из библиотеки Peptides. Авторство и содержание оригинала сохранены. Размещено с разрешения поставщика.